melphalan

The common side effect in intravenous melphalan is mucositis .

黏膜炎是静脉马法兰应用后最常见的副反应；

Melphalan antitumor activity is through blocking the duplication of DNA of tumor cells .

马法兰、强的松的抗肿瘤主要作用是分别通过阻断DNA的复制和促使其断裂而达到抑制肿瘤细胞生长的目的。

TBI , Melphalan with autologous bone marrow transplantation for malignant lymphomas

马法兰联合全身照射的自体骨髓移植治疗恶性淋巴瘤

Method : 2mg of melphalan were used every two days to treat 13 cases of highly dangerous myelodysplastic syndromes .

方法：应用马法兰2mg，隔日一次口服，治疗高危骨髓增生异常综合征13例。

Report on the autologous transplant mainly conditioned with intravenous melphalan in 43 chinese children with advanced malignant solid tumours

以静脉马法兰为主的预处理自身移植治疗43例儿童高危恶性实体肿瘤

Clinical efficacy of thalidomide with melphalan and prednison in the treatment of 23 cases multiple myeloma

沙立度胺联合MP化疗方案治疗多发性骨髓瘤23例

Adverse events were consistent with established profiles of toxic events associated with bortezomib and melphalan – prednisone .

在已建立的毒性事件谱上，硼替佐米组和对照组副作用两组一致。

Background The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone .

对于不适合大剂量治疗的多发性骨髓瘤患者，他们的标准治疗方案是马法兰加泼尼松。

Methods Retrospective analysis for autologous transplant mainly with intravenous melphalan in 43 children with advanced malignant solid tumours was performed in our center .

方法用回顾性分析的方法，对43例以静脉马法兰为主的预处理移植治疗的儿童高危恶性肿瘤临床资料进行分析。

Small-dosage melphalan treatment for middle and highly-dangerous myelodysplastic syndrome and invert acute medullary system leucemia

马法兰治疗骨髓增生异常综合征及其转化的急性髓系白血病临床观察

Methods : In March 2003 , we adopted Isolated Liver Perfusion ( ILP ) with melphalan under high temperature in the treatment of an unresectable primary liver tumor .

方法2003年3月，在治疗不可切除性原发性肝癌中采用了高温下马法兰隔离肝灌注治疗。

Objective : This paper is designed to observe the effect of small dosage melphalan on highly dangerous myelodysplastic syndromes ( RAEB , RAEB T ) .

目的：观察小剂量马法兰治疗高危骨髓增生异常综合征，即原始细胞过多的难治性贫血（RAEB）和转变中的原始细胞过多的难治性贫血（RAEB-T）的疗效。

The standard conventional therapy is the combination of melphalan and prednisone resulting in a response rate of 40 % - 60 % and in a median survival time of approximately 3 years .

一般保守疗法是采用左旋苯丙氨酸联合强的松用药，有效率可达40%～60%，平均存活时间大约为3年。

210 mg / m2 of melphalan should be considered as the right dosage when the number of stem cells is enough and the potential of bone marrow recovery is good after sequence chemotherapy .

对于干细胞数量充足、化疗后骨髓恢复能力尚佳的移植患者以210mg/m2的马法兰剂量为妥；